Pfizer/Neurocrine Indiplon NDA Expected Mid-Year; Long-Term Data Reported
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies’ upcoming submissions will cover immediate- and modified-release formulations. Two pivotal three-month studies of indiplon show highly statistically significant results for sleep onset and total sleep time.
You may also be interested in...
Pfizer/Neurocrine File First Indiplon NDA With Eye On Fourth Quarter 2005 Launch
Filing for immediate-release formulation of insomnia agent will be followed by extended-release submission in November, Neurocrine says. A simultaneous launch is planned. Firms are highlighting long-term use, middle-of-the-night dosing.
Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter
The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.